|
NCCN Guidelines® Insights - Survivorship, Version 2.2025 |
1.00 |
06/10/2025 - 12:00am to 06/10/2026 - 12:00am |
|
NCCN Guidelines® Insights - Survivorship, Version 2.2024 |
1.00 |
12/10/2024 - 12:00am to 12/10/2025 - 12:00am |
|
NCCN Guidelines® Insights - Rectal Cancer, Version 3.2024 |
1.00 |
08/10/2024 - 12:00am to 08/10/2025 - 12:00am |
|
NCCN Guidelines® Insights - Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024 |
1.00 |
10/10/2024 - 12:00am to 10/10/2025 - 12:00am |
|
NCCN Guidelines® Insights - Myelodysplastic Syndromes, Version 2.2025 |
1.00 |
03/10/2025 - 12:00am to 03/10/2026 - 12:00am |
|
NCCN Guidelines® Insights - Multiple Myeloma, Version 1.2025 |
1.00 |
05/10/2025 - 12:00am to 05/10/2026 - 12:00am |
|
NCCN Guidelines® Insights - Melanoma: Cutaneous, Version 2.2024 |
1.00 |
07/10/2024 - 12:00am to 07/10/2025 - 12:00am |
|
NCCN Guidelines® Insights - Management of Immunotherapy-Related Toxicities, Version 2.2024 |
1.00 |
11/10/2024 - 12:00am to 11/10/2025 - 12:00am |
|
NCCN Guidelines® Insights - Lung Cancer Screening, Version 1.2025 |
1.00 |
01/10/2025 - 12:00am to 01/10/2026 - 12:00am |
|
NCCN Guidelines® Insights - Head and Neck Cancers, Version 2.2025 |
1.00 |
02/10/2025 - 12:00am to 02/10/2026 - 12:00am |
|
NCCN Guidelines® Insights - Colorectal Cancer Screening, Version 1.2024 |
1.00 |
09/10/2024 - 12:00am to 09/10/2025 - 12:00am |
|
Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care |
1.50 |
06/30/2025 - 12:00am to 12/30/2025 - 11:59pm |
|
Myelodysplastic Syndromes: Treatment Updates and Emerging Data |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Managing Pain in Cancer Survivors |
0.25 |
08/04/2022 - 12:00am to 08/04/2025 - 12:00am |
Facebook
Twitter
LinkedIn
Forward